<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95915">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02097056</url>
  </required_header>
  <id_info>
    <org_study_id>ARI-M082-401</org_study_id>
    <nct_id>NCT02097056</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease</brief_title>
  <acronym>SAVE</acronym>
  <official_title>Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Korea Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Food and Drug Safety, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, single-arm, prospective, phase IV trial, evaluating
      safety and efficacy of donepezil hydrochloride in patients with moderate to severe
      Alzheimer's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consisted of pre-treatment and treatment phase. Pre-treatment phase was
      approximately 4 weeks including the screening and baseline process. In treatment phase,
      about 190 subjects received Donepezil HCl 23 mg once daily for 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety of Donepezil HCl 23 mg once daily</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety will be evaluated by all adverse events, serious adverse events, discontinuation from the treatment, prior and concomitant medication, clinical laboratory determinations (biochemistry, blood, urine test), vital signs, weight, ECG, and physical examination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Donepezil HCl 23 mg once daily</measure>
    <time_frame>Baseline, Week 12, and Week 24 (Final visit)</time_frame>
    <safety_issue>No</safety_issue>
    <description>MMSE (Mini-Mental State Examination) and NPI-Q (Brief questionnaire form of the Neuropsychiatric Inventory) score will be used to evaluate efficacy. Mean change will be analyzed by paired t-test or Wilcoxon's signed rank test.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>donepezil HCl 23 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil HCl 23 mg once daily, just before bed, for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>donepezil HCL</intervention_name>
    <description>Donepezil HCl 23 mg once daily, just before bed, for 24 weeks</description>
    <arm_group_label>donepezil HCl 23 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Male or female aged 45 to 90 years

          2. Patients have eligible conditions of dementia diagnosis listed in DSM-IV

          3. Diagnosed as a probable Alzheimer's Disease patient according to NINCDS-ADRDA
             criteria

          4. At the timing of screening, MMSE less than or equal to 20 AND CDR greater than or
             equal to 2 OR GDS greater than or equal to 4

          5. Patients, who have been taking stable donepezil 10 mg for 3 months or longer before
             the start of the study (screening visit), are evaluated as eligible to take donepezil
             23 mg by investigator

          6. Patients who have not received any other medications for AD such as AChE inhibitors
             at least for 3 months prior to the screening visit excluding donepezil hydrochloride
             (However, concomitant use of memantine is allowed if taken at stable dose that are
             less than or equal to the approved dose range for at least 3 months prior to
             screening)

          7. Medicines for cerebral activation such as Gingko Biloba is allowed to be taken if the
             patient has received it as stable dose for 3 months prior to the screening visit

        Exclusion Criteria

          1. Patients who have been participated in any other clinical trial 3 months prior to the
             screening visit

          2. Patients who are having any severe psychiatric disorder or schizophrenia

          3. Patients who are having a neurological disorder other than AD which affect the
             subject's cognition or ability to assess the cognition
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Youngji Pyo</last_name>
    <phone>+82-2-3451-5533</phone>
    <email>y-pyo@eisaikorea.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Chungju</city>
        <state>Chungcheongbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Gumi</city>
        <state>Geyongsangbuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ansan</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Buchoen</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jinju</city>
        <state>Gyeongsangnam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Iksan</city>
        <state>Jeollabuk-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hwasun</city>
        <state>Jeollanam-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>March 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
